Invitae Executive Compensation (FY22)
NVTA · Executive and director compensation, fiscal 2022 only
Chief executive, fiscal 2022 ◇ Kenneth Knight | Latest say-on-pay support = June 6, 2022 |
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
The paid brief on Invitae
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Data as of October 18, 2026Latest filing (DEF 14A): April 19, 2023
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Velarion Intel, one year, every company
131 figures on this page: 128 cited to the filing that reported them, 3 calculated from figures it prints. See the citations
More on Invitae
Five data products on this company. Each one is requested through the developer setup page.
- Peer Disclosure Audit$5The comparison companies this board named, each one tied to the filing that lists it.How to get Peer Disclosure Audit
- Governance Provisions PullfreeThe governance provisions as the proxy states them: board leadership, committee membership, and shareholder rights.How to get Governance Provisions Pull
- Say-on-Pay Risk Signal$9A risk band for the next say-on-pay vote, with the support history and the peer comparison behind it.How to get Say-on-Pay Risk Signal
- NEO Comp Report$24Every named executive officer’s pay by element and year, with the citation behind each figure.How to get NEO Comp Report
- Board Comp Report$24What each non-employee director was paid, the standing fee schedule, and the equity each one holds at year end.How to get Board Comp Report
Frequently asked questions
Answers drawn from the data on this page.
Who is Invitae's chief executive and what were they paid?
Kenneth Knight, Chief Executive Officer, received $4,950,752 in total compensation for fiscal 2022.
What was Invitae's say-on-pay result?
Shareholders supported the say-on-pay proposal with 95.5% of votes cast including abstentions in favor at the meeting held June 6, 2022 for fiscal 2021.
Which companies are in Invitae's peer group?
Companies named in the disclosed peer group include ACADIA Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, BioMarin Pharmaceutical and CareDx, among others.
Executive compensation
Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
| Officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|---|
Kenneth Knight Chief Executive Officer | ◇ | — | ◇ | ◇ | ◇ | — | ◇ | ◇ |
Yafei Wen Chief Financial Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Thomas Brida General Counsel, Chief Compliance Officer and Secretary | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Robert Nussbaum Chief Medical Officer | ◇ | — | ◇ | — | ◇ | — | ◇ | ◇ |
Sean George Former President and Chief Executive Officer Departed during or after this year | ◇ | — | — | — | ◇ | — | ◇ | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.
Equity awards granted
Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2022
| Officer | Award | Grant date | Threshold units | Target units | Units granted | Maximum units | Exercise price | Grant date fair value |
|---|---|---|---|---|---|---|---|---|
| Kenneth D. Knight | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Kenneth D. Knight | OPTION | ◇ | — | — | ◇ | — | ◇ | ◇ |
| Robert L. Nussbaum | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Robert L. Nussbaum | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Thomas R. Brida | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Thomas R. Brida | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Yafei Wen | RSU | ◇ | — | — | ◇ | — | — | ◇ |
| Yafei Wen | RSU | ◇ | — | — | ◇ | — | — | ◇ |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.
Outstanding awards
Awards still held at fiscal year end.
As disclosed at fiscal 2022 year end
| Officer | Award | Unvested units | Market value of unvested units | Exercise price | Expires |
|---|---|---|---|---|---|
| Kenneth Knight | Option | ◇ | — | ◇ | 7/16/2032 |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 4/30/2031 | |
| RSU | ◇ | ◇ | — | — | |
| Yafei Wen | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Robert Nussbaum | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 4/30/2031 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 6/12/2030 | |
| Thomas Brida | RSU | ◇ | ◇ | — | — |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 4/30/2031 | |
| RSU | ◇ | ◇ | — | — | |
| Option | ◇ | — | ◇ | 6/12/2030 | |
| Sean George | RSU | ◇ | ◇ | — | — |
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director compensation
What each non-employee director was paid.
Fiscal 2022
| Director | Fees earned in cash | Stock awards | Option awards | Non-equity incentive | Pension and deferred earnings | All other compensation | Total |
|---|---|---|---|---|---|---|---|
Eric Aguiar, MD Lead independent director | — | — | — | — | — | — | — |
Christine M. Gorjanc | — | — | — | — | — | — | — |
Geoffrey S. Crouse | — | — | — | — | — | — | — |
Kimber D. Lockhart | — | — | — | — | — | — | — |
Chitra Nayak | — | — | — | — | — | — | — |
Randal W. Scott, PhD Board chair | ◇ | ◇ | ◇ | — | — | — | ◇ |
Sean E. George, PhD | ◇ | ◇ | ◇ | — | — | — | ◇ |
Kenneth D. Knight and William H. Osborne served on the board in fiscal 2022 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.
Director fee schedule
The standing retainers and premiums the board pays, as published.
| Board cash retainer | ◇ |
| Board equity retainer | ◇ |
| Total board retainer | ◇ |
| Board chair premium | ◇ |
| Lead independent director premium | ◇ |
| Audit committee chair | ◇ |
| Audit committee member | ◇ |
| Compensation committee chair | ◇ |
| Compensation committee member | ◇ |
| Nominating and governance chair | ◇ |
| Nominating and governance member | ◇ |
Equity is delivered as Rsus/Options.
Disclosed peer group
The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2022
- ACADIA Pharmaceuticals ACAD
- Alnylam Pharmaceuticals ALNY
- Arrowhead Pharmaceuticals ARWR
- BioMarin Pharmaceutical BMRN
- CareDx CDNA
- Exact Sciences EXAS
- iRhythm Technologies IRTC
- Maravai LifeSciences MRVI
- Natera NTRA
- Neogen NEOG
- Nevro NVRO
- QuidelOrtho QDEL
- Sarepta Therapeutics SRPT
Say-on-pay history
Shareholder support for the compensation program, by year.
| Year | Meeting | Support | Votes for | Votes against | Abstentions |
|---|---|---|---|---|---|
| 2021 | June 6, 2022 | = | ◇ | ◇ | ◇ |
| 2020 | June 7, 2021 | = | ◇ | ◇ | ◇ |
| 2019 | June 8, 2020 | = | ◇ | ◇ | ◇ |
Ask our research desk — $99, 24h, every figure cited to its filing.
Sample answer — “What is the CEO’s total compensation?”
- Kenneth Knight (Chief Executive Officer), FY2022 total compensation $4,950,752 (base salary $610,577) [exec_comp, SEC accession 0001308179-23-000696, filed 2023-04-19]What this page does not include
Everything above is a fact Invitae disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Invitae sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion IntelligenceAdviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about accessMultiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion IntelligenceCitations
Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
131 figures on this page: 128 cited to the filing that reported them, 3 calculated from figures it prints.
128 cited to the filing
3 calculated from the filing
Documents cited
- 0001308179-23-000696Director Compensation · Grants of Plan-Based Awards Table · Outstanding Equity Awards at Fiscal Year-End Table · Summary Compensation Table
- 0001193125-22-172012
- 0001193125-21-188305Item 404(a) of Regulation S-K. The foregoing summary of the Offer Letter is qualified in its entirety by reference to the Offer Letter, a copy of which is attached hereto as Exhibit 10.1 and incorpora
- 0001193125-20-167744
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Invitae executive compensation, FY2022.” https://intel.velarion.ai/comp/NVTA (accessed 2026).
Short form: data: Velarion
The paid brief for Invitae
Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
4 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Invitae and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Peers Invitae discloses
The companies named in NVTA's own disclosed peer group.
Terms on this page
Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.
Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
author = {{Velarion Company Intelligence}},
title = {Velarion database: executive and board compensation data},
year = {2026},
version = {2026Q3},
doi = {10.5281/zenodo.22283854},
publisher = {Zenodo},
url = {https://doi.org/10.5281/zenodo.22283854}
}